REFERENCES
- Aardema M. J., MacGregor J. T. Toxicology and genetic toxicology in the new era of “toxicogenomics”: Impact of “-omics” technologies. Mutat. Res. 2002; 499(1)13–25, [PUBMED], [INFOTRIEVE], [CSA]
- Afshari C. A., Nuwaysir E. F., Barrett J. C. Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation. Cancer Res. 1999; 59(19)4759–4760, [PUBMED], [INFOTRIEVE], [CSA]
- Alizadeh A. A., Eisen M. B., Davis R. E., Ma C., Lossos I. S., Rosenwald A., Boldrick J. C., Sabet H., Tran T., Yu X., Powell J. I., Yang L., Marti G. E., Moore T., Hudson J., Jr., Lu L., Lewis D. B., Tibshirani R., Sherlock G., Chan W. C., Greiner T. C., Weisenburger D. D., Armitage J. O., Warnke R., Levy R., Wilson W., Grever M. R., Byrd J. C., Botstein D., Brown P. O., Staudt L. M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [see comments]. Nature 2000; 403(6769)503–511, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bataller R., Brenner D. A. Liver fibrosis. J. Clin. Invest. 2005; 115(2)209–218, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bittner M., Meltzer P., Chen Y., Jiang Y., Seftor E., Hendrix M., Radmacher M., Simon R., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F., Gooden C., Lueders J., Glatfelter A., Pollock P., Carpten J., Gillanders E., Leja D., Dietrich K., Beaudry C., Berens M., Alberts D., Sondak V. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406(6795)536–540, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bulera S. J., Eddy S. M., Ferguson E., Jatkoe T. A., Reindel J. F., Bleavins M. R., De La Iglesia F. A. RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays. Hepatology 2001; 33(5)1239–1258, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Burczynski M. E., McMillian M., Ciervo J., Li L., Parker J. B., Dunn R. T., 2nd, Hicken S., Farr S., Johnson M. D. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol. Sci. 2000; 58(2)399–415, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cunningham M. L., Lehman-McKeeman L. Applying toxicogenomics in mechanistic and predictive toxicology. Toxicol. Sci. 2005; 83(2)205–206, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Farr S., Dunn R. T., 2nd. Concise review: Gene expression applied to toxicology. Toxicol Sci 1999; 50(1)1–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 1987; 317(20)1237–1245, [PUBMED], [INFOTRIEVE], [CSA]
- Fuhrman S., Cunningham M. J., Wen X., Zweiger G., Seilhamer J. J., Somogyi R. The application of shannon entropy in the identification of putative drug targets. Biosystems 2000; 55(1–3)5–14, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Garrett M. D., Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur. J. Cancer. 1999; 35(14)2010–2030, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Golub T. R., Slonim D. K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J. P., Coller H., Loh M. L., Downing J. R., Caligiuri M. A., Bloomfield C. D., Lander E. S. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999; 286(5439)531–537, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gonzalez F. J., Peters J. M., Cattley R. C. Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor alpha. J. Natl. Cancer. Inst. 1998; 90(22)1702–1709, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hamadeh H. K., Bushel P. R., Jayadev S., DiSorbo O., Bennett L., Li L., Tennant R., Stoll R., Barrett J. C., Paules R. S., Blanchard K., Afshari C. A. Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 2002; 67(2)232–240, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hamadeh H. K., Bushel P. R., Jayadev S., Martin K., DiSorbo O., Sieber S., Bennett L., Tennant R., Stoll R., Barrett J. C., Blanchard K., Paules R. S., Afshari C. A. Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. 2002; 67(2)219–231, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hamadeh H. K., Knight B. L., Haugen A. C., Sieber S., Amin R. P., Bushel P. R., Stoll R., Blanchard K., Jayadev S., Tennant R. W., Cunningham M. L., Afshari C. A., Paules R. S. Methapyrilene toxicity: Anchorage of pathologic observations to gene expression alterations. Toxicol. Pathol. 2002; 30(4)470–482, [PUBMED], [INFOTRIEVE], [CSA]
- Hertz R., Bar-Tana J. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Toxicol. Lett. 1998; 102–103: 85–90, [CROSSREF], [CSA]
- Huang Q., Dunn R. T., 2nd, Jayadev S., DiSorbo O., Pack F. D., Farr S. B., Stoll R. E., Blanchard K. T. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci. 2001; 63(2)196–207, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lesko L. J., Atkinson A. J., Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 347–366, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Madias N. E., Harrington J. T. Platinum nephrotoxicity. Am. J. Med. 1978; 65(2)307–314, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Naveau S., Raynard B., Ratziu V., Abella A., Imbert-Bismut F., Messous D., Beuzen F., Capron F., Thabut D., Munteanu M., Chaput J. C., Poynard T. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin. Gastroenterol Hepatol. 2005; 3(2)167–174, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nuwaysir E. F., Bittner M., Trent J., Barrett J. C., Afshari C. A. Microarrays and toxicology: The advent of toxicogenomics. Mol. Carcinog. 1999; 24(3)153–159, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Palmer C. N., Hsu M. H., Griffin K. J., Raucy J. L., Johnson E. F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 1998; 53(1)14–22, [PUBMED], [INFOTRIEVE], [CSA]
- Perou C. M., Sorlie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Rees C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge O., Pergamenschikov A., Williams C., Zhu S. X., Lonning P. E., Borresen-Dale A. L., Brown P. O., Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406(6797)747–752, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Peters J. M., Cattley R. C., Gonzalez F. J. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997; 18(11)2029–2033, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Poynard T., Abella A., Pignon J. P., Naveau S., Leluc R., Chaput J. C. Apolipoprotein AI and alcoholic liver disease. Hepatology 1986; 6(6)1391–1395, [PUBMED], [INFOTRIEVE], [CSA]
- Poynard T., Aubert A., Bedossa P., Abella A., Naveau S., Paraf F., Chaput J. C. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991; 100(5 Pt 1)1397–1402, [PUBMED], [INFOTRIEVE], [CSA]
- Poynard T., Imbert-Bismut F., Munteanu M., Messous D., Myers R. P., Thabut D., Ratziu V., Mercadier A., Benhamou Y., Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp. Hepatol. 2004; 3(1)8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Poynard T., Imbert-Bismut F., Munteanu M., Ratziu V. FibroTest-FibroSURE: Towards a universal biomarker of liver fibrosis?. Expert. Rev. Mol. Diagn. 2005; 5(1)15–21, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Roberts R. A. Peroxisome proliferators: Mechanisms of adverse effects in rodents and molecular basis for species differences. Arch. Toxicol. 1999; 73(8–9)413–418, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ruepp S., Boess F., Suter L., de Vera M. C., Steiner G., Steele T., Weiser T., Albertini S. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol. Appl. Pharmacol. 2005; 207(2 Suppl)161–170, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schena M., Heller R. A., Theriault T. P., Konrad K., Lachenmeier E., Davis R. W. Microarrays: Biotechnology's discovery platform for functional genomics. Trends Biotechnol. 1998; 16(7)301–306, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Scherf U., Ross D. T., Waltham M., Smith L. H., Lee J. K., Tanabe L., Kohn K. W., Reinhold W. C., Myers T. G., Andrews D. T., Scudiero D. A., Eisen M. B., Sausville E. A., Pommier Y., Botstein D., Brown P. O., Weinstein J. N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000; 24(3)236–244, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Steiner G., Suter L., Boess F., Gasser R., de Vera M. C., Albertini S., Ruepp S. Discriminating different classes of toxicants by transcript profiling. Environ. Health Perspect. 2004; 112(12)1236–1248, [PUBMED], [INFOTRIEVE], [CSA]
- Suter L., Babiss L. E., Wheeldon E. B. Toxicogenomics in predictive toxicology in drug development. Chem. Biol. 2004; 11(2)161–171, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Suter L., Haiker M., De Vera M. C., Albertini S. Effect of two 5-HT6 receptor antagonists on the rat liver: A molecular approach. Pharmacogenomics J. 2003; 3(6)320–334, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Teare J. P., Sherman D., Greenfield S. M., Simpson J., Bray G., Catterall A. P., Murray-Lyon I. M., Peters T. J., Williams R., Thompson R. P. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993; 342(8876)895–898, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thomas R. S., Rank D. R., Penn S. G., Zastrow G. M., Hayes K. R., Pande K., Glover E., Silander T., Craven M. W., Reddy J. K., Jovanovich S. B., Bradfield C. A. Identification of toxicologically predictive gene sets using cDNA microarrays. Mol. Pharmacol. 2001; 60(6)1189–1194, [PUBMED], [INFOTRIEVE], [CSA]
- Thukral S. K., Nordone P. J., Hu R., Sullivan L., Galambos E., Fitzpatrick V. D., Healy L., Bass M. B., Cosenza M. E., Afshari C. A. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol. Pathol. 2005; 33(3)343–355, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tugwood J. D., Aldridge T. C., Lambe K. G., Macdonald N., Woodyatt N. J. Peroxisome proliferator-activated receptors: Structures and function. Ann. N.Y. Acad. Sci. 1996; 804: 252–265, [PUBMED], [INFOTRIEVE], [CSA]
- Vogelzang N. J. Nephrotoxicity from chemotherapy: Prevention and management. Oncology (Williston Park) 1991; 5(10)97–102, 105; disc 105, 109-111[CSA]
- Waring J. F., Ciurlionis R., Jolly R. A., Heindel M., Ulrich R. G. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 2001; 120(1–3)359–368, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Waring J. F., Jolly R. A., Ciurlionis R., Lum P. Y., Praestgaard J. T., Morfitt D. C., Buratto B., Roberts C., Schadt E., Ulrich R. G. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 2001; 175(1)28–42, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Waring J. F., Ulrich R. G. The impact of genomics-based technologies on drug safety evaluation. Annu Rev Pharmacol Toxicol 2000; 40: 335–352, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zhou T., Jia X., Chapin R. E., Maronpot R. R., Harris M. W., Liu J., Waalkes M. P., Eddy E. M. Cadmium at a non-toxic dose alters gene expression in mouse testes. Toxicol. Lett. 2004; 154(3)191–200, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]